Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patientsStefano Cascinu, Rossana Berardi, Alberto Zaniboni et al.|European Journal of Cancer|2017Cited by 30
Survher: A retrospective multicenter study comparing demographic and tumor characteristics of clinical trials versus clinical practice patients with HER2-positive breast cancer.Grazia Arpino, Sabino De Placido, Mauro Truini et al.|Journal of Clinical Oncology|2014Cited by 0